Economic Observation Network Qiming Medical plans to complete equity financing in the first half of 2026 and intends to introduce a single controlling shareholder. The current management team and Qiming Venture Capital hold a total shareholding ratio of 10% -15%. The expected proportion of this additional issuance is over 20%, which may bring a capital injection of HKD 300-500 million to the company At the same time, the company continues to promote the disposal of non core assets, has withdrawn from minority equity investments such as Dejin Medical, and plans to exit the Picardia project in Israel in 2026, which is expected to bring at least 100 million yuan in cash inflows ?

Company Status
By 2025, the domestic TAVR (Transcatheter Aortic Valve Replacement) implantation volume will decrease to 3600 units (a year-on-year decrease of 14%), and revenue will decrease by about 50% year-on-year, mainly due to the direct sales and distribution model leading to a decrease in factory prices. Expected year-on-year growth of 10% -15% in implantation volume in the domestic market by 2026 ?

The above content is based on publicly available information and does not constitute investment advice.